| 1 |
Nguyen NM, Cho J, Lee C. Gut Microbiota and Alzheimer's Disease: How to Study and Apply Their Relationship. Int J Mol Sci 2023;24. [PMID: 36835459 DOI: 10.3390/ijms24044047] [Reference Citation Analysis]
|
| 2 |
Gowen R, Gamal A, Di Martino L, McCormick TS, Ghannoum MA. Modulating the Microbiome for Crohn's Disease Treatment. Gastroenterology 2023:S0016-5085(23)00049-5. [PMID: 36702360 DOI: 10.1053/j.gastro.2023.01.017] [Reference Citation Analysis]
|
| 3 |
Zhang L, Xiang Y, Li Y, Zhang J. Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications. Front Immunol 2022;13:1058272. [PMID: 36569873 DOI: 10.3389/fimmu.2022.1058272] [Reference Citation Analysis]
|
| 4 |
Dubik M, Pilecki B, Moeller JB. Commensal Intestinal Protozoa-Underestimated Members of the Gut Microbial Community. Biology (Basel) 2022;11. [PMID: 36552252 DOI: 10.3390/biology11121742] [Reference Citation Analysis]
|
| 5 |
Yu J, Cheon JH. Microbial Modulation in Inflammatory Bowel Diseases. Immune Netw 2022;22:e44. [PMID: 36627937 DOI: 10.4110/in.2022.22.e44] [Reference Citation Analysis]
|
| 6 |
Varesi A, Campagnoli LIM, Fahmideh F, Pierella E, Romeo M, Ricevuti G, Nicoletta M, Chirumbolo S, Pascale A. The Interplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment. Int J Mol Sci 2022;23:12289. [PMID: 36293176 DOI: 10.3390/ijms232012289] [Reference Citation Analysis]
|
| 7 |
Caetano MAF, Castelucci P. Role of short chain fatty acids in gut health and possible therapeutic approaches in inflammatory bowel diseases. World J Clin Cases 2022; 10(28): 9985-10003 [DOI: 10.12998/wjcc.v10.i28.9985] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Nigam M, Panwar AS, Singh RK. Orchestrating the fecal microbiota transplantation: Current technological advancements and potential biomedical application. Front Med Technol 2022;4. [DOI: 10.3389/fmedt.2022.961569] [Reference Citation Analysis]
|
| 9 |
Li H, Miao MX, Jia CL, Cao YB, Yan TH, Jiang YY, Yang F. Interactions between Candida albicans and the resident microbiota. Front Microbiol 2022;13:930495. [PMID: 36204612 DOI: 10.3389/fmicb.2022.930495] [Reference Citation Analysis]
|
| 10 |
Shi G, Kong J, Wang Y, Xuan Z, Xu F. Glycyrrhiza uralensis fisch. Alleviates dextran sulfate sodium-induced colitis in mice through inhibiting of NF-κB signaling pathways and modulating intestinal microbiota. J Ethnopharmacol 2022;:115640. [PMID: 36030029 DOI: 10.1016/j.jep.2022.115640] [Reference Citation Analysis]
|
| 11 |
Xue S, Xue Y, Dou D, Wu H, Zhang P, Gao Y, Tang Y, Xia Z, Yang S, Gu S, Tu W. Kui Jie Tong Ameliorates Ulcerative Colitis by Regulating Gut Microbiota and NLRP3/Caspase-1 Classical Pyroptosis Signaling Pathway. Disease Markers 2022;2022:1-15. [DOI: 10.1155/2022/2782112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Panpetch W, Phuengmaung P, Hiengrach P, Issara-amphorn J, Cheibchalard T, Somboonna N, Tumwasorn S, Leelahavanichkul A. Candida Worsens Klebsiella pneumoniae Induced-Sepsis in a Mouse Model with Low Dose Dextran Sulfate Solution through Gut Dysbiosis and Enhanced Inflammation. IJMS 2022;23:7050. [DOI: 10.3390/ijms23137050] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 13 |
Wang X, Zhao J, Feng Y, Feng Z, Ye Y, Liu L, Kang G, Cao X. Evolutionary Insights Into Microbiota Transplantation in Inflammatory Bowel Disease. Front Cell Infect Microbiol 2022;12:916543. [DOI: 10.3389/fcimb.2022.916543] [Reference Citation Analysis]
|
| 14 |
Mariño E. SCFAs in T1D: A microbiota-targeted approach for immune tolerance. Current Opinion in Endocrine and Metabolic Research 2022;24:100355. [DOI: 10.1016/j.coemr.2022.100355] [Reference Citation Analysis]
|
| 15 |
Yusuf K, Saha S, Umar S. Health Benefits of Dietary Fiber for the Management of Inflammatory Bowel Disease. Biomedicines 2022;10:1242. [DOI: 10.3390/biomedicines10061242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 16 |
Mindt BC, Digiandomenico A. Microbiome Modulation as a Novel Strategy to Treat and Prevent Respiratory Infections. Antibiotics 2022;11:474. [DOI: 10.3390/antibiotics11040474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 17 |
Farooq RK, Alamoudi W, Alhibshi A, Rehman S, Sharma AR, Abdulla FA. Varied Composition and Underlying Mechanisms of Gut Microbiome in Neuroinflammation. Microorganisms 2022;10:705. [DOI: 10.3390/microorganisms10040705] [Reference Citation Analysis]
|
| 18 |
Liu J, Gao Z, Liu C, Liu T, Gao J, Cai Y, Fan X. Alteration of Gut Microbiota: New Strategy for Treating Autism Spectrum Disorder. Front Cell Dev Biol 2022;10:792490. [DOI: 10.3389/fcell.2022.792490] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 19 |
Cibulková I, Řehořová V, Duška F. Importance of intestinal microbiota in critically ill patients and possibilities of its influence. Anest intenziv Med 2022;33:32-38. [DOI: 10.36290/aim.2022.003] [Reference Citation Analysis]
|
| 20 |
Larussa T, Abenavoli L, Fabiano G, Mancuso MA, Polimeni N, Dumitrascu DL, Luzza F. Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.21.02907-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Neuman H, Turjeman S, Koren O. The Gut Microbiome. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00040-7] [Reference Citation Analysis]
|
| 22 |
Laudes M, Geisler C, Rohmann N, Bouwman J, Pischon T, Schlicht K. Microbiota in Health and Disease-Potential Clinical Applications. Nutrients 2021;13:3866. [PMID: 34836121 DOI: 10.3390/nu13113866] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 23 |
Varesi A, Deumer US, Ananth S, Ricevuti G. The Emerging Role of Gut Microbiota in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Current Evidence and Potential Therapeutic Applications. J Clin Med 2021;10:5077. [PMID: 34768601 DOI: 10.3390/jcm10215077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 24 |
Salliss ME, Farland LV, Mahnert ND, Herbst-Kralovetz MM. The role of gut and genital microbiota and the estrobolome in endometriosis, infertility and chronic pelvic pain. Hum Reprod Update 2021:dmab035. [PMID: 34718567 DOI: 10.1093/humupd/dmab035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 25 |
Deumer US, Varesi A, Floris V, Savioli G, Mantovani E, López-Carrasco P, Rosati GM, Prasad S, Ricevuti G. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview. J Clin Med 2021;10:4786. [PMID: 34682909 DOI: 10.3390/jcm10204786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 26 |
Cibulková I, Řehořová V, Hajer J, Duška F. Fecal Microbial Transplantation in Critically Ill Patients-Structured Review and Perspectives. Biomolecules 2021;11:1459. [PMID: 34680092 DOI: 10.3390/biom11101459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Ho M, Moon D, Pires-Alves M, Thornton PD, McFarlin BL, Wilson BA. Recovery of microbial community profile information hidden in chimeric sequence reads. Comput Struct Biotechnol J 2021;19:5126-39. [PMID: 34589188 DOI: 10.1016/j.csbj.2021.08.050] [Reference Citation Analysis]
|
| 28 |
Koutouratsas T, Philippou A, Kolios G, Koutsilieris M, Gazouli M. Role of exercise in preventing and restoring gut dysbiosis in patients with inflammatory bowel diseases: A review. World J Gastroenterol 2021; 27(30): 5037-5046 [PMID: 34497433 DOI: 10.3748/wjg.v27.i30.5037] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 29 |
Jo HG, Seo GS. [Efficacy and Safety of Fecal Microbiota Transplantation and Prospect of Microbe-based Therapies for Inflammatory Bowel Disease]. Korean J Gastroenterol 2021;78:31-6. [PMID: 34312355 DOI: 10.4166/kjg.2021.089] [Reference Citation Analysis]
|
| 30 |
Li Y, Honda K. Towards the development of defined microbial therapeutics. Int Immunol 2021:dxab038. [PMID: 34232990 DOI: 10.1093/intimm/dxab038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 31 |
Özdirik B, Müller T, Wree A, Tacke F, Sigal M. The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. Int J Mol Sci 2021;22:6975. [PMID: 34203536 DOI: 10.3390/ijms22136975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 32 |
Sorokina E, Zhgun E, Kislun Y, Denisova E, Bespyatykh Y, Ilina E. Optimization of Conditions for Human Bacterial Preparation for Biological Correction of Intestinal Microflora. BMCRM 2021;4:e00151. [DOI: 10.18097/bmcrm00151] [Reference Citation Analysis]
|
| 33 |
Kropp C, Le Corf K, Relizani K, Tambosco K, Martinez C, Chain F, Rawadi G, Langella P, Claus SP, Martin R. The Keystone commensal bacterium Christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo. Sci Rep 2021;11:11494. [PMID: 34075098 DOI: 10.1038/s41598-021-90885-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 34 |
Bunt DV, Minnaard AJ, El Aidy S. Potential Modulatory Microbiome Therapies for Prevention or Treatment of Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:506. [PMID: 34073220 DOI: 10.3390/ph14060506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 35 |
Schmidt C, Grunert PC, Stallmach A. An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective. Front Pharmacol 2021;12:655054. [PMID: 33912062 DOI: 10.3389/fphar.2021.655054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 36 |
Yang T, Chakraborty S, Mandal J, Mei X, Joe B. Microbiota and Metabolites as Factors Influencing Blood Pressure Regulation. Compr Physiol 2021;11:1731-57. [PMID: 33792901 DOI: 10.1002/cphy.c200009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
